HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

IMPACT THERAP-B

36.760

-0.240-0.65%

Volume:1K

Turnover:43.70K

Market Cap:10.38B

PE:-25.51

High:36.800

Open:36.800

Low:36.220

Close:37.000

52wk High:47.980

52wk Low:28.200

Shares:282.46M

HK Float Shares:282.46M

Volume Ratio:0.07

T/O Rate:0.00%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-1.441

ROE:--

ROA:-40.35%

PB:-9.36

PE(LYR):-25.51

PS:234.46

Loading ...

Overview Company News Filings

IMPACT Therapeutics boosts share capital by 2.30 % through full over-allotment option exercise

Bulletin Express

IMPACT THERAP-B Issues 6.3 Million H Shares Upon Full Exercise of Over-Allotment Option

IMPACT Therapeutics Concludes Stabilization; 6.30 Million H Shares Allotted at HK$20.10 Each

Bulletin Express

IMPACT THERAP-B Concludes Stabilization Period with Full Exercise of Over-Allotment Option

Impact Therapeutics Nets HK$120 Million From Full Exercise of IPO Overallotment Option

MT Newswires Live

IMPACT Therapeutics Raises HK$119.50 Million via Full Exercise of 15% Over-Allotment Option

Bulletin Express

IMPACT THERAP-B Fully Exercises Over-Allotment Option

Transcenta names Hansen Xu non-executive director, Jun Bao independent director

IMPACT Therapeutics Sets 25 June 2026 AGM; Shareholders to Vote on 2025 Results, Auditor Re-Appointment and Dual Mandates

Bulletin Express

IMPACT Therapeutics Sets 25 June 2026 AGM; Board Requests 20% Issuance Mandate and 10% H-Share Buy-back Authority

Bulletin Express

Impact Therapeutics announces annual shareholder meeting

IMPACT THERAP-B (07630) to Unveil Phase I/II Trial Results for IMP1734 at 2026 ASCO Annual Meeting

IMPACT Therapeutics highlights IMP1734 Phase 1/2 data at ASCO 2026; monotherapy ORR 14.3%, paclitaxel combo ORR 24.5%

Bulletin Express

Impact Therapeutics says PARP1 inhibitor IMP1734 posts 14.3% ORR in Phase 1/2 monotherapy data at ASCO 2026

Stock Track | Impact Therapeutics-B Soars 15.59% Intraday in Strong Rebound After Post-IPO Profit-Taking

Movement Alert｜Impact Therapeutics-B Rises 13.17% in Regular Trading, Strong Rebound After Post-IPO Profit-Taking

Stock Track | Impact Therapeutics-B Plummets 5.18% Intraday on Post-IPO Profit-Taking and Weak Fundamentals

Movement Alert｜Impact Therapeutics-B Falls 5.77% in Regular Trading, Post-IPO Profit-Taking Pressure Emerges After 108% First-Day Surge

IMPACT THERAP-B Surges Nearly 4% in Late Trading as Core Drug Senaparib Secured National Reimbursement Last December

Stock Track | Impact Therapeutics-B Soars 6.95% Intraday on Medical Insurance Inclusion and Pipeline Progress

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/07630/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"07630","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"07630\",,,,,undefined,":{"symbol":"07630","market":"HK","secType":"STK","nameCN":"IMPACT THERAP-B","latestPrice":36.76,"timestamp":1781228934083,"preClose":37,"halted":0,"volume":1200,"delay":0,"changeRate":-0.00648648648648654,"floatShares":282461530,"shares":282461530,"eps":-1.440772,"marketStatus":"Trading","change":-0.24,"latestTime":"06-12 09:50:53","open":36.8,"high":36.8,"low":36.22,"amount":43696,"amplitude":0.015676,"askPrice":36.76,"askSize":400,"bidPrice":36.5,"bidSize":200,"shortable":0,"etf":0,"ttmEps":-1.16,"tradingStatus":2,"nextMarketStatus":{"tag":"Noon Closed","tradingStatus":4,"beginTime":1781236800000},"marketStatusCode":2,"adr":0,"listingDate":1778601600000,"exchange":"SEHK","adjPreClose":37,"openAndCloseTimeList":[[1781227800000,1781236800000],[1781240400000,1781251200000]],"volumeRatio":0.068953,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"07630\",,,,,undefined,":{"symbol":"07630","floatShares":282461530,"roa":"-40.35%","roe":"--","lyrEps":-1.440772,"volumeRatio":0.068953,"shares":282461530,"dividePrice":0,"high":36.8,"amplitude":0.015676,"preClose":37,"low":36.22,"week52Low":28.2,"pbRate":"-9.36","psRate":"234.46","week52High":47.98,"institutionHeld":0,"latestPrice":36.76,"committee":-0.333333,"eps":-1.440772,"divideRate":0,"volume":1200,"delay":0,"ttmEps":-1.16,"open":36.8,"prevYearClose":20.1,"prevWeekClose":37.02,"prevMonthClose":39.9,"prevQuarterClose":20.1,"fiveDayClose":37.02,"twentyDayClose":40,"sixtyDayClose":20.1},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/07630\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"07630\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"07630\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/07630\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"07630","date":"2026-06-10","current":-31.896552,"percent":0.85,"low":-34.323153,"twenty":-32.344912,"median":-30.958502,"eighty":-29.849738,"high":-16.800385,"avg":-30.407128,"sd":3.543955,"marketCap":10135260271},"quantilePoints":[{"date":"2026-05-15","current":-32.36994,"twenty":-32.973318,"median":-32.357426,"eighty":-26.127101,"marketCap":11057651805},{"date":"2026-05-22","current":-30.548005,"twenty":-32.354923,"median":-30.958502,"eighty":-28.393426,"marketCap":10411425401},{"date":"2026-05-29","current":-32.218614,"twenty":-32.294393,"median":-30.958502,"eighty":-30.148817,"marketCap":11018988687},{"date":"2026-06-05","current":-29.849738,"twenty":-32.359929,"median":-31.257987,"eighty":-30.148817,"marketCap":10223633112},{"date":"2026-06-10","current":-29.609087,"twenty":-32.344912,"median":-30.958502,"eighty":-29.849738,"marketCap":10135260271}],"updateTime":1781210326613},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"07630\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1157701649","title":"IMPACT Therapeutics boosts share capital by 2.30 % through full over-allotment option exercise","url":"https://stock-news.laohu8.com/highlight/detail?id=1157701649","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157701649?lang=en_us&edition=fundamental","pubTime":"2026-06-11 06:23","pubTimestamp":1781130203,"startTime":"0","endTime":"0","summary":"IMPACT Therapeutics, Inc. (IMPACT THERAP-B) reported that the joint global coordinators fully exercised the over-allotment option on 10 June 2026, resulting in the issuance and allotment of 6.30...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150770934","title":"IMPACT THERAP-B Issues 6.3 Million H Shares Upon Full Exercise of Over-Allotment Option","url":"https://stock-news.laohu8.com/highlight/detail?id=1150770934","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150770934?lang=en_us&edition=fundamental","pubTime":"2026-06-11 06:16","pubTimestamp":1781129774,"startTime":"0","endTime":"0","summary":"IMPACT THERAP-B (HKEX: 07630) has announced that on June 10, 2026, it issued and allotted 6.2964 million H shares as a result of the full exercise of the over-allotment option.","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179114095","title":"IMPACT Therapeutics Concludes Stabilization; 6.30 Million H Shares Allotted at HK$20.10 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=1179114095","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179114095?lang=en_us&edition=fundamental","pubTime":"2026-06-08 17:03","pubTimestamp":1780909380,"startTime":"0","endTime":"0","summary":"IMPACT Therapeutics, Inc. (IMPACT Therapeutics) announced the completion of its post-listing stabilization period on 7 June 2026, exactly 30 days after the close of the Hong Kong Public Offering....","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132981482","title":"IMPACT THERAP-B Concludes Stabilization Period with Full Exercise of Over-Allotment Option","url":"https://stock-news.laohu8.com/highlight/detail?id=1132981482","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132981482?lang=en_us&edition=fundamental","pubTime":"2026-06-08 16:56","pubTimestamp":1780909011,"startTime":"0","endTime":"0","summary":"The stabilization period relating to the company's global offering concluded on Sunday, June 7, 2026, which is the 30th day after the deadline for submitting Hong Kong public offering...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641172548","title":"Impact Therapeutics Nets HK$120 Million From Full Exercise of IPO Overallotment Option","url":"https://stock-news.laohu8.com/highlight/detail?id=2641172548","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641172548?lang=en_us&edition=fundamental","pubTime":"2026-06-08 09:15","pubTimestamp":1780881354,"startTime":"0","endTime":"0","summary":"Impact Therapeutics  said the overallotment option of its Hong Kong initial public offering was fully exercised on Friday, according to a same-day Hong Kong bourse filing.The Chinese biopharmaceutical company expects to raise about HK$119.5 million in additional net proceeds.The exercise involved the issue of 6.3 million additional H-shares at HK$20.10 each, representing about 15% of the total offer shares initially available under the global offering.Dealings in the overallotment shares are expected to begin on June 10, the filing said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IPOS","BK4139","BK4539","BK4007","LENZ","BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199847182","title":"IMPACT Therapeutics Raises HK$119.50 Million via Full Exercise of 15% Over-Allotment Option","url":"https://stock-news.laohu8.com/highlight/detail?id=1199847182","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199847182?lang=en_us&edition=fundamental","pubTime":"2026-06-05 21:03","pubTimestamp":1780664606,"startTime":"0","endTime":"0","summary":"IMPACT Therapeutics, Inc. announced that the overall coordinators have fully exercised the 15% over-allotment option linked to the company’s recent Hong Kong IPO. An additional 6.30 million H shares...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152339070","title":"IMPACT THERAP-B Fully Exercises Over-Allotment Option","url":"https://stock-news.laohu8.com/highlight/detail?id=1152339070","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152339070?lang=en_us&edition=fundamental","pubTime":"2026-06-05 20:56","pubTimestamp":1780664180,"startTime":"0","endTime":"0","summary":"IMPACT THERAP-B (07630) has announced that the over-allotment option detailed in the prospectus has been fully exercised by the overall coordinators on Friday, June 5, 2026. This action, taken on...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640138154","title":"Transcenta names Hansen Xu non-executive director, Jun Bao independent director","url":"https://stock-news.laohu8.com/highlight/detail?id=2640138154","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640138154?lang=en_us&edition=fundamental","pubTime":"2026-06-04 19:19","pubTimestamp":1780571941,"startTime":"0","endTime":"0","summary":"Transcenta set to add Hansen Xu as non-executive director, pending shareholder vote at a June 30, 2026 AGM.Xu has been an investment manager since 2021, now a vice president at Liyan Enterprise Management Consulting ; previously a BCG consultant.Jun Bao to rejoin as independent non-executive director, also subject to the AGM vote; he previously served on the board from March 2021 to August 2023.Bao is chief business officer at Biotheus since 2022; previously CEO of Impact Therapeutics, with earlier business development roles at GSK and Onyx.Independent directors Kumar Srinivasan and Zhihua Zhang to step down once the appointments take effect; board committee leadership to be reshuffled.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tr","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nNDL7M7ZQ1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06628","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123127100","title":"IMPACT Therapeutics Sets 25 June 2026 AGM; Shareholders to Vote on 2025 Results, Auditor Re-Appointment and Dual Mandates","url":"https://stock-news.laohu8.com/highlight/detail?id=1123127100","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123127100?lang=en_us&edition=fundamental","pubTime":"2026-06-03 19:05","pubTimestamp":1780484712,"startTime":"0","endTime":"0","summary":"IMPACT Therapeutics, Inc. has circulated a proxy form ahead of its 2025 Annual General Meeting, scheduled for 10:00 a.m. on Thursday, 25 June 2026, at the Board Room, 27F, New Bund Times Square, 399...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183390771","title":"IMPACT Therapeutics Sets 25 June 2026 AGM; Board Requests 20% Issuance Mandate and 10% H-Share Buy-back Authority","url":"https://stock-news.laohu8.com/highlight/detail?id=1183390771","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183390771?lang=en_us&edition=fundamental","pubTime":"2026-06-03 18:43","pubTimestamp":1780483434,"startTime":"0","endTime":"0","summary":"IMPACT Therapeutics, Inc. has convened its 2026 Annual General Meeting (AGM) for 10:00 a.m. on 25 June 2026 at the company’s Board Room, 27F, New Bund Times Square, 399 West Haiyang Road, Pudong...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640905626","title":"Impact Therapeutics announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2640905626","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640905626?lang=en_us&edition=fundamental","pubTime":"2026-06-03 18:34","pubTimestamp":1780482850,"startTime":"0","endTime":"0","summary":"Impact Therapeutics will hold its annual general meeting in Shanghai on June 25, 2026.Shareholders will vote on the 2025 board work report, the accountant’s report for 2025, and the 2025 profit distribution plan.Other items include re-appointing Ernst & Young as auditor for 2026, proposed amendments to the articles of association.Resolutions also cover a general mandate to issue shares up to 20% of shares in issue, plus a mandate to repurchase up to 10% of H shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Impact Therapeutics Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange  , on June 03, 2026, and is solely responsible for the ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nNDL1q597b:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190630928","title":"IMPACT THERAP-B (07630) to Unveil Phase I/II Trial Results for IMP1734 at 2026 ASCO Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=1190630928","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1190630928?lang=en_us&edition=fundamental","pubTime":"2026-06-01 08:40","pubTimestamp":1780274422,"startTime":"0","endTime":"0","summary":"IMPACT THERAP-B (07630) announced that the latest Phase I/II clinical data for the highly selective PARP1 inhibitor IMP1734 (also known as EIK1003) will be presented in a poster session at the 2026...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199921042","title":"IMPACT Therapeutics highlights IMP1734 Phase 1/2 data at ASCO 2026; monotherapy ORR 14.3%, paclitaxel combo ORR 24.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1199921042","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199921042?lang=en_us&edition=fundamental","pubTime":"2026-06-01 08:23","pubTimestamp":1780273420,"startTime":"0","endTime":"0","summary":"IMPACT Therapeutics, Inc. (IMPACT Therapeutics) released updated Phase 1/2 clinical results for its PARP1-selective inhibitor IMP1734 (EIK1003) during the 2026 American Society of Clinical Oncology...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640890009","title":"Impact Therapeutics says PARP1 inhibitor IMP1734 posts 14.3% ORR in Phase 1/2 monotherapy data at ASCO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2640890009","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640890009?lang=en_us&edition=fundamental","pubTime":"2026-06-01 08:06","pubTimestamp":1780272383,"startTime":"0","endTime":"0","summary":"Impact Therapeutics presented Phase 1/2 data for PARP1 inhibitor IMP1734 at the 2026 ASCO Annual Meeting.Monotherapy showed early signs of durable tumor shrinkage in heavily pretreated patients, with a generally favorable safety profile.A separate cohort combining IMP1734 with weekly paclitaxel showed antitumor activity despite extensive prior taxane use.The combination produced manageable safety in an advanced-line setting, with severe side effects largely consistent with chemotherapy-driven blood toxicities.Data support a strategy to pair a PARP1-selective inhibitor with cytotoxic chemotherapy, an approach the company framed as difficult with older PARP drugs.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Impact Therapeutics Inc. pu","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDLgDcQN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107678797","title":"Stock Track | Impact Therapeutics-B Soars 15.59% Intraday in Strong Rebound After Post-IPO Profit-Taking","url":"https://stock-news.laohu8.com/highlight/detail?id=1107678797","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107678797?lang=en_us&edition=fundamental","pubTime":"2026-05-22 11:16","pubTimestamp":1779419803,"startTime":"0","endTime":"0","summary":"Impact Therapeutics-B's stock surged 15.59% intraday, staging a significant rebound in the Hong Kong market. The movement represents a recovery following several sessions of profit-taking pressure...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119583328","title":"Movement Alert｜Impact Therapeutics-B Rises 13.17% in Regular Trading, Strong Rebound After Post-IPO Profit-Taking","url":"https://stock-news.laohu8.com/highlight/detail?id=1119583328","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119583328?lang=en_us&edition=fundamental","pubTime":"2026-05-22 11:14","pubTimestamp":1779419673,"startTime":"0","endTime":"0","summary":"On May 22, Impact Therapeutics-B (07630.HK) rose 13.17% in regular trading, trading at HK$35.68 per share, with trading volume of approximately HK$8.79 million. The stock staged a strong rebound...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116682247","title":"Stock Track | Impact Therapeutics-B Plummets 5.18% Intraday on Post-IPO Profit-Taking and Weak Fundamentals","url":"https://stock-news.laohu8.com/highlight/detail?id=1116682247","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116682247?lang=en_us&edition=fundamental","pubTime":"2026-05-21 10:32","pubTimestamp":1779330773,"startTime":"0","endTime":"0","summary":"Impact Therapeutics-B's stock plummeted 5.18% during intraday trading on Thursday.The decline reflects mounting profit-taking pressure following the company's explosive IPO debut. Impact Therapeutics...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162485828","title":"Movement Alert｜Impact Therapeutics-B Falls 5.77% in Regular Trading, Post-IPO Profit-Taking Pressure Emerges After 108% First-Day Surge","url":"https://stock-news.laohu8.com/highlight/detail?id=1162485828","media":"Market Focus","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162485828?lang=en_us&edition=fundamental","pubTime":"2026-05-21 10:31","pubTimestamp":1779330674,"startTime":"0","endTime":"0","summary":"On May 21, Impact Therapeutics-B (07630.HK) declined 5.77% in regular trading, trading at HK$35.7 per share, with trading volume of approximately HK$5.39 million.The decline reflects mounting...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186114537","title":"IMPACT THERAP-B Surges Nearly 4% in Late Trading as Core Drug Senaparib Secured National Reimbursement Last December","url":"https://stock-news.laohu8.com/highlight/detail?id=1186114537","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186114537?lang=en_us&edition=fundamental","pubTime":"2026-05-19 15:52","pubTimestamp":1779177169,"startTime":"0","endTime":"0","summary":"IMPACT THERAP-B (07630) rose nearly 4% in late trading. As of press time, the stock was up 3.93% to HK$39.66, with a turnover of HK$13.8225 million. Public information indicates that IMPACT THERAP-B...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VXUS","07630","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147308533","title":"Stock Track | Impact Therapeutics-B Soars 6.95% Intraday on Medical Insurance Inclusion and Pipeline Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=1147308533","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147308533?lang=en_us&edition=fundamental","pubTime":"2026-05-15 09:41","pubTimestamp":1778809313,"startTime":"0","endTime":"0","summary":"IMPACT THERAP-B (stock code: 07630) saw its stock price soar by 6.95% during intraday trading on Friday, extending its strong performance since its recent listing.The surge is attributed to multiple...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":40,"code":"91000000","status":"200"}]}}